MAPT and supranuclear palsy, progressive, 1: We argue that a potential key confound of [18F]PI-2620 PET quantification in 4R tauopathies like PSP is the choice of an optimal reference region used to scale the tau-PET signal in pathology harboring regions against an ideally pathology free region.